{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:57:03Z","timestamp":1791478623441,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Five distinct medulloblastoma cell lines (ONS76, UW228-3, DAOY, D283, D425) were exposed to varying radiation doses and fractionation schemes. In addition, ONS76 and UW228-3 stably overexpressing MYC were analyzed. Alpha\/beta values, representing fractionation sensitivity, were quantified using the linear-quadratic model of radiation survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study unveiled elevated alpha\/beta ratios across diverse medulloblastoma cell lines, with a weighted mean alpha\/beta value of 11.01\u00a0Gy (CI: 5.23\u201316.79\u00a0Gy). Neither TP53 status nor the levels of MYC expression influenced fractionated radiosensitivity. Furthermore, differences in alpha\/beta values cannot be correlated with molecular subgroups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07) or radiosensitivity (SF2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These in vitro findings strongly recommend normofractionated or hyperfractionated radiotherapy for paediatric medulloblastoma cases due to consistently high alpha\/beta values across subgroups. Conversely, hypofractionated radiotherapy is not advisable within a curative approach. This study presents significant potential by enabling the estimation of radiobiological fractionations and dose effects in young, vulnerable patients, highlighting its importance for advancing patient-specific therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-024-02566-8","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T13:50:48Z","timestamp":1738158648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Alpha\/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology"],"prefix":"10.1186","volume":"20","author":[{"given":"Danny","family":"Jazmati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"B\u00f6lke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Haussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas David","family":"Niggemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Babor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triantafyllia","family":"Brozou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Felek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balint","family":"Tamaskovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Beez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Remke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi Till","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja-Linda","family":"Preugschas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Budach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Matuschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"3","key":"2566_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clon.2019.01.001","volume":"31","author":"L Padovani","year":"2019","unstructured":"Padovani L, Horan G, Ajithkumar T. Radiotherapy advances in Paediatric Medulloblastoma Treatment. Clin Oncol (R Coll Radiol). 2019;31(3):171\u201381. https:\/\/doi.org\/10.1016\/j.clon.2019.01.001.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2566_CR2","doi-asserted-by":"publisher","unstructured":"Seidel C, Heider S, Hau P, Glasow A, Dietzsch S, Kortmann RD. Radiotherapy in Medulloblastoma-Evolution of Treatment, current concepts and future perspectives. Cancers (Basel). 2021;13(23). https:\/\/doi.org\/10.3390\/cancers13235945. (In eng).","DOI":"10.3390\/cancers13235945"},{"issue":"8","key":"2566_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106. (In eng).","journal-title":"Neuro Oncol"},{"issue":"1","key":"2566_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40478-022-01326-7","volume":"10","author":"B Lee","year":"2022","unstructured":"Lee B, Mahmud I, Pokhrel R, et al. Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs. Acta Neuropathol Commun. 2022;10(1):25. https:\/\/doi.org\/10.1186\/s40478-022-01326-7. (In eng).","journal-title":"Acta Neuropathol Commun"},{"issue":"19","key":"2566_CR5","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1200\/jco.2011.34.9373","volume":"29","author":"M Remke","year":"2011","unstructured":"Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29(19):2717\u201323. https:\/\/doi.org\/10.1200\/jco.2011.34.9373. (In eng).","journal-title":"J Clin Oncol"},{"issue":"3","key":"2566_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccell.2018.08.002","volume":"34","author":"A Forget","year":"2018","unstructured":"Forget A, Martignetti L, Puget S, et al. Aberrant ERBB4-SRC signaling as a Hallmark of Group 4 Medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell. 2018;34(3):379\u2013e3957. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.002. (In eng).","journal-title":"Cancer Cell"},{"issue":"6","key":"2566_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13311-022-01273-0","volume":"19","author":"MA Lazow","year":"2022","unstructured":"Lazow MA, Palmer JD, Fouladi M, Salloum R. Medulloblastoma in the modern era: review of contemporary trials, molecular advances, and updates in management. Neurotherapeutics. 2022;19(6):1733\u201351. https:\/\/doi.org\/10.1007\/s13311-022-01273-0. (In eng).","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2566_CR8","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1038\/s41598-020-66328-8","volume":"10","author":"R Fri\u010d","year":"2020","unstructured":"Fri\u010d R, Due-T\u00f8nnessen BJ, Lundar T, et al. Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood. Sci Rep. 2020;10(1):9371. https:\/\/doi.org\/10.1038\/s41598-020-66328-8. (In eng).","journal-title":"Sci Rep"},{"issue":"7","key":"2566_CR9","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.clon.2021.03.006","volume":"33","author":"D Jazmati","year":"2021","unstructured":"Jazmati D, Steinmeier T, Ahamd Khalil D, et al. Feasibility of Proton Beam Therapy for Infants with Brain tumours: experiences from the prospective KiProReg Registry Study. Clin Oncol (R Coll Radiol). 2021;33(7):e295\u2013304. https:\/\/doi.org\/10.1016\/j.clon.2021.03.006. (In eng).","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"2566_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/jco.2008.18.4176","volume":"27","author":"L Gandola","year":"2009","unstructured":"Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol. 2009;27(4):566\u201371. https:\/\/doi.org\/10.1200\/jco.2008.18.4176. (In eng).","journal-title":"J Clin Oncol"},{"issue":"26","key":"2566_CR11","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/jco.2011.39.8719","volume":"30","author":"B Lannering","year":"2012","unstructured":"Lannering B, Rutkowski S, Doz F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. 2012;30(26):3187\u201393. https:\/\/doi.org\/10.1200\/jco.2011.39.8719. (In eng).","journal-title":"J Clin Oncol"},{"issue":"1","key":"2566_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen CM, Oei AL, Crezee J, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):96. https:\/\/doi.org\/10.1186\/s13014-018-1040-z. (In eng).","journal-title":"Radiat Oncol"},{"key":"2566_CR13","doi-asserted-by":"crossref","unstructured":"Qin N, Paisana E, Langini M, Picard D, Malzkorn B, Cust\u00f3dia C, Casc\u00e3o R, Meyer FD, Bl\u00fcmel L, G\u00f6bbels S, Taban K, Bartl J, Bechmann N, Conrad C, Gravemeyer J, Becker JC, Stefanski A, Puget S, Barata JT, St\u00fchler K, Fischer U, Felsberg J, Ayrault O, Reifenberger G, Borkhardt A, Eisenhofer G, Faria CC, Remke M. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis Abstract Neuro Oncol. 2022; 24(9) 1509-1523 10.1093\/neuonc\/noac068","DOI":"10.1093\/neuonc\/noac068"},{"key":"2566_CR14","doi-asserted-by":"crossref","unstructured":"J\u00e4nicke RU, Sprengart ML, Wati MR, Porter AG..Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis. J Biol Chem. 1998; 273(16) 9357-9360 10.1074\/jbc.273.16.9357","DOI":"10.1074\/jbc.273.16.9357"},{"key":"2566_CR15","doi-asserted-by":"crossref","unstructured":"Budach W, Gioioso D, Taghian A, Stuschke M, Suit HD. Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys 1997;39:743\u201350. https:\/\/doi.org\/10.1016\/s0360-3016(97)00362-3.","DOI":"10.1016\/S0360-3016(97)00362-3"},{"key":"2566_CR16","doi-asserted-by":"crossref","unstructured":"Lehnert S, Greene D, Batist G. Radiation response of drug-resistant variants of a human breast cancer cell line. Radiat Res 1989;118:568\u201380.","DOI":"10.2307\/3577414"},{"issue":"3","key":"2566_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0360-3016(93)90389-d","volume":"27","author":"M Stuschke","year":"1993","unstructured":"Stuschke M, Budach V, Sack H. Radioresponsiveness of human glioma, sarcoma, and breast cancer spheroids depends on tumor differentiation. Int J Radiat Oncol Biol Phys. 1993;27(3):627\u201336. https:\/\/doi.org\/10.1016\/0360-3016(93)90389-d. (In eng).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2566_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0360-3016(95)00528-7","volume":"32","author":"M Stuschke","year":"1995","unstructured":"Stuschke M, Budach V, St\u00fcben G, Streffer C, Sack H. Heterogeneity in the fractionation sensitivities of human tumor cell lines: studies in a three-dimensional model system. Int J Radiat Oncol Biol Phys. 1995;32(2):395\u2013408. https:\/\/doi.org\/10.1016\/0360-3016(95)00528-7. (In eng).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2566_CR19","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1038\/s41596-021-00615-0","volume":"16","author":"N Brix","year":"2021","unstructured":"Brix N, Samaga D, Belka C, Zitzelsberger H, Lauber K. Analysis of clonogenic growth in vitro. Nat Protoc. 2021;16(11):4963\u201391. https:\/\/doi.org\/10.1038\/s41596-021-00615-0. (In eng).","journal-title":"Nat Protoc"},{"issue":"12","key":"2566_CR20","doi-asserted-by":"publisher","first-page":"Cd002026","DOI":"10.1002\/14651858.CD002026.pub2","volume":"2010","author":"B Baujat","year":"2010","unstructured":"Baujat B, Bourhis J, Blanchard P, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;2010(12):Cd002026. https:\/\/doi.org\/10.1002\/14651858.CD002026.pub2. (In eng).","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2566_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-016-2202-1","volume":"129","author":"M Sabel","year":"2016","unstructured":"Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129(3):515\u201324. https:\/\/doi.org\/10.1007\/s11060-016-2202-1. (In eng).","journal-title":"J Neurooncol"},{"issue":"5","key":"2566_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.ijrobp.2015.04.023","volume":"92","author":"H C\u00e2mara-Costa","year":"2015","unstructured":"C\u00e2mara-Costa H, Resch A, Kieffer V, et al. Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy. Int J Radiat Oncol Biol Phys. 2015;92(5):978\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.023. (In eng).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2566_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijrobp.2007.09.044","volume":"71","author":"DL Anghelescu","year":"2008","unstructured":"Anghelescu DL, Burgoyne LL, Liu W, et al. Safe anesthesia for radiotherapy in pediatric oncology: St. Jude Children\u2019s Research Hospital Experience, 2004\u20132006. Int J Radiat Oncol Biol Phys. 2008;71(2):491\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.09.044. (In eng).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2566_CR24","doi-asserted-by":"publisher","unstructured":"Taylor RE, Howman AJ, Wheatley K, Brogden EE, Large B, Gibson MJ, Robson K, Mitra D, Saran F, Michalski A, Pizer BL. Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma\u2014a safety\/feasibility study. Radiother Oncol. 2014 Apr;111(1):41\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2014.01.022.","DOI":"10.1016\/j.radonc.2014.01.022"},{"key":"2566_CR25","doi-asserted-by":"publisher","unstructured":"Williams AB, Schumacher B. p53 in the DNA-Damage-repair process. Cold Spring Harb Perspect Med. 2016;6(5). https:\/\/doi.org\/10.1101\/cshperspect.a026070. (In eng).","DOI":"10.1101\/cshperspect.a026070"},{"issue":"1","key":"2566_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2. (In eng).","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2566_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/cdd.2008.33","volume":"15","author":"RU J\u00e4nicke","year":"2008","unstructured":"J\u00e4nicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15(6):959\u201376. https:\/\/doi.org\/10.1038\/cdd.2008.33. (In eng).","journal-title":"Cell Death Differ"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02566-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T13:50:55Z","timestamp":1738158655000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02566-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02566-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4707241\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to our ethics commission board, ethical approval was not deemed necessary for the irradiation of cell lines, as it is not a mandatory requirement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}